A phase III, randomised, double-blind, multi-dose, placebo- and naproxen-controlled study to evaluate the efficacy and safety of fasinumab in patients with pain due to osteoarthritis of the knee or hip.

RMD Open · 2026 · PMC12815151 · PMID 41545313

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Nominally significant differences for fasinumab 1 mg Q4W versus placebo and naproxen were also observed for ≥50% and ≥70% reductions in WOMAC pain subscale score at week 16 ( figure 3B ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.